REG - Adv Medical Soln Grp - Notice of Results

Advanced Medical SolutionsAnnouncement

03/09/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200903:nRSC8820Xa

RNS Number : 8820X  Advanced Medical Solutions Grp PLC  03 September 2020

03 September 2020

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Notice of Interim Results

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical
and advanced wound care specialist company, will announce its interim results
for the six months ended 30 June 2020 on Wednesday, 16 September 2020.

 

A virtual briefing for analysts will be held at 9:30am BST on the day of the
results. For more information on the conference call, please contact
AMS@consilium-comms.com.

 

- End -

 

 

 

 

For further information, please contact:

 

 Advanced Medical Solutions Group plc              Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Consilium Strategic Communications                Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Olivia Manser

 Investec Bank PLC (NOMAD & Broker)                Tel: +44 (0) 20 7597 5970
 Daniel Adams / Patrick Robb / Gary Clarence

 

 

About Advanced Medical Solutions Group plc

 

AMS is a world-leading developer and manufacturer of innovative and
technologically advanced products for the global surgical and woundcare
markets, focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives, sutures,
haemostats, and internal fixation devices, which it markets under its brands
LiquiBand(®), RESORBA(®), and LiquiBandFix8(®). AMS also supplies wound
care dressings such as silver alginates, alginates and foams through its
ActivHeal(®) brand as well as under white label. In 2019, the Group made two
acquisitions: Sealantis, an Israeli medical device company with a
patent-protected sealant technology platform; and Biomatlante, an established
developer and manufacturer of innovative surgical biomaterial technologies
based in France.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, and
the Czech Republic, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has approximately 700 employees. For more information, please
see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDZGGLMZLGGZZ